Rio Olympian Ian Lariba diagnosed with leukemia | Inquirer Sports

Rio Olympian Ian Lariba diagnosed with leukemia

/ 12:23 PM May 30, 2017

Ian Lariba

Philippines’ Ian Lariba hits a shot in her women’s singles qualification round table tennis match at the Riocentro venue during the Rio 2016 Olympic Games in Rio de Janeiro on August 6, 2016. AFP FILE PHOTO

Rio Olympian Ian Lariba has been diagnosed with Acute Myeloid Leukemia (AML), her family disclosed Tuesday.

In a statement released by DLSU Sports, Lariba’s family shared that the 22-year-old Lasallian paddler will undergo treatment this week after seeking blood donors to help her cause late since last week.

Article continues after this advertisement

“We request the Lasallian community to extend assistance and support to Yan Yan during this time,” the statement read.

FEATURED STORIES

The school also urged the community to extend financial assistance to Lariba’s family during their time of need.

Article continues after this advertisement

She dominated the UAAP table tennis field in her five-year stint for the Green Paddlers where she became a three-time Most Valuable Player, Rookie of the Year in Season 74, and the UAAP Athlete of the Year in Seasons 77 and 78.

Lariba earned a ticket to the 2016 Rio Olympics, becoming the Philippines’ first table tennis representative to the quadrennial meet.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Ian Lariba, leukemia, Rio Olympics, table tennis

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.